Patents by Inventor Jacques Dumas

Jacques Dumas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8207166
    Abstract: The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: June 26, 2012
    Assignee: Bayer Healthcare LLC
    Inventors: Wendy Lee, Gaetan Ladouceur, Jacques Dumas, Roger Smith, Shihong Ying, Gan Wang, Zhi Chen, Qingjie Liu, Holia Mokdad
  • Publication number: 20120149706
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: February 21, 2012
    Publication date: June 14, 2012
    Inventors: Jacques DUMAS, Uday KHIRE, Timothy B. Lowinger, Holger PAULSEN, Bernd RIEDL, Willian J. SCOTT, Roger A. SMITH, Jill WOOD, Holia HATOUM-MOKDAD, Wendy LEE, Aniko REDMAN, Jeffrey JOHNSON, Robert SIBLEY
  • Publication number: 20120142742
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: February 8, 2012
    Publication date: June 7, 2012
    Applicant: BAYER HEALTHERCARE LLC
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood
  • Publication number: 20120136157
    Abstract: This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
    Type: Application
    Filed: February 3, 2012
    Publication date: May 31, 2012
    Inventors: Jacques Dumas, William J. Scott, Du-Shieng Chien, Ala Nassar, Wendy Lee, Susan Bjorge, Laszlo L. Musza, Bernd Riedl
  • Publication number: 20120129893
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 24, 2012
    Inventors: Jacques DUMAS, Uday Khire, Timothy B. Lowinger, Holger Paulsen, Bernd Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Wendy Lee, Aniko Redman, Robert Sibley, Joel Renick
  • Publication number: 20120053179
    Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
    Type: Application
    Filed: November 4, 2011
    Publication date: March 1, 2012
    Inventors: Dhanapalan Nagarathnam, Jacques Dumas, Holia Hatoum-Mokdad, Stephen Boyer, Chunguang Wang, Hans Pluempe, Achim Feurer, Samir Bennabi
  • Patent number: 8124630
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: February 28, 2012
    Assignee: Bayer Healthcare LLC
    Inventors: Bernd Riedl, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Reina Natero
  • Publication number: 20120046290
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 23, 2012
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Holger Paulsen, Bernd Riedl, William J. Scott, Roger A. Smith, Jill Wood, Holia Hatoum-Mokdad, Wendy Lee, Aniko Redman, Jeffrey Johnson, Robert Sibley
  • Publication number: 20120040986
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: August 11, 2011
    Publication date: February 16, 2012
    Inventors: Bernd RIEDL, Jacques DUMAS, Uday KHIRE, Timothy B. LOWINGER, William J. SCOTT, Roger A. SMITH, Jill E. WOOD, Mary-Katherine MONAHAN, Reina NATERO, Joel RENICK, Robert N. SIBLEY
  • Patent number: 8110587
    Abstract: This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: February 7, 2012
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, Bernd Riedl, Du-Schieng Chien, Ala Nassar, Wendy Lee, Susan Bjorge, Laszlo Musza
  • Patent number: 8076488
    Abstract: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: December 13, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, Stephen Boyer, Sharad Verma, Lila Adnane, Yuanwei Chen, Wendy Lee, Barton Phillips, Roger A. Smith, William J. Scott, Jennifer Burke, Jianqing Chen, Zhi Chen, Jianmei Fan, Karl Miranda, Brian Raudenbush, Aniko Redman, Jianxing Shao, Ning Su, Gan Wang, Lin Yi, Qingming Zhu
  • Patent number: 8071616
    Abstract: This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: December 6, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, William J. Scott, Bernd Riedl
  • Publication number: 20110294776
    Abstract: This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer.
    Type: Application
    Filed: November 2, 2006
    Publication date: December 1, 2011
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stephen O'Connor, Jacques Dumas, Wendy Lee, Julie Dixon, David Cantin, David Gunn, Jennifer Burke, Barton Phillips, Derek Lowe, Tatiana Shelekhin, Gan Wang, Xin Ma, Shihong Ying, Andrea McClure, Furahi Achebe, Mario Lobell, Frederick Ehrgott, Christiana Iwuagwu, Kyle Parcella
  • Publication number: 20110178064
    Abstract: In one aspect, the present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to method for their preparation.
    Type: Application
    Filed: July 16, 2008
    Publication date: July 21, 2011
    Applicant: ASTRAZENECA R&D
    Inventors: Gregory Steven Basarab, Jacques Dumas, Pamela Hill
  • Publication number: 20110172224
    Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.
    Type: Application
    Filed: August 19, 2005
    Publication date: July 14, 2011
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Chengzhi Zhang, Jacques Dumas, Qingming Zhu, Roger Smith, Qingjie Liu, Sharad Verma, Jason Duquette, Qian Zhao, Dongping Fan, Georgiy Bondar, Philip Coish
  • Publication number: 20110136809
    Abstract: The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).
    Type: Application
    Filed: November 8, 2010
    Publication date: June 9, 2011
    Applicant: Bayer Pharmaceuticals Corporation
    Inventors: Wendy LEE, Gaetan LADOUCEUR, Jacques DUMAS, Roger SMITH, Shihong YING, Gan WANG, Zhi CHEN, Qingjie LIU, Holia Hatoum MOKDAD
  • Patent number: 7928239
    Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: April 19, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Jacques Dumas, Bernd Riedl, Uday Khire, Jill E. Wood, Robert N. Sibley, Mary-Katherine Monahan, Joel Renick, David E. Gunn, Timothy B. Lowinger, William J. Scott, Roger A. Smith
  • Patent number: 7928227
    Abstract: This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: April 19, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Stephen Boyer, Jacques Dumas, Barton Phillips, William J. Scott, Roger A. Smith, Jianqing Chen, Benjamin Jones, Gan Wang
  • Patent number: 7897623
    Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: March 1, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Bernd Riedl, Jacques Dumas, Uday R. Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, Mary-Katherine Monahan, Reina Natero, Joel Renick, Robert N. Sibley
  • Publication number: 20110015195
    Abstract: This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
    Type: Application
    Filed: September 23, 2010
    Publication date: January 20, 2011
    Inventors: Jacques Dumas, William J. Scott, James Elting, Holia Hatoum-Makdad